BIOMEDICINE & PHARMACOTHERAPY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2226246, encodeId=b83e222624679, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：药学 经验分享：投完之后就后悔了 2个月就中了博士第一篇SCI 感觉以后会是污点但是为了毕业也是无奈之举单纯要毕业可以投如果不担心毕业别投了以后真的是污点现在真的后悔因为 2个月之后中了 SCIENCE SIGNALING , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c8550067, createdName=ms1000000538363514, createdTime=Tue Sep 17 20:03:25 CST 2024, time=2024-09-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232434, encodeId=a6562232434b3, content=On hold了！快跑！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a35599610, createdName=ms3000000650032694, createdTime=Tue Oct 22 14:04:58 CST 2024, time=2024-10-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233015, encodeId=96d12233015e5, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理学;癌症;神经退行性疾病 经验分享：《BIOMEDICINE & PHARMACOTHERAPY》，中文名《生物医学与药物治疗》在10月21日被on hold。 《BIOMEDICINE & PHARMACOTHERAPY》是医学—药学类目SCI期刊，创刊于1982年，由Elsevier 出版，该期刊主要发表生物医学和药理学相关的研究，涉及癌症、营养学、神经退行性疾病、心脏病和传染病的分子机制，正常和病理细胞的基因调节以及对致癌物质的敏感性，药物对临床前和临床药理学的影响，细菌、病毒和寄生虫在动物和人类中的作用等。国人喜欢这本期刊是因为该期刊对中医药研究比较友好。 中科院预警情况：2020年预警等级：中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Fri Oct 25 05:38:32 CST 2024, time=2024-10-25, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2232150, encodeId=bd1d2232150e3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：中药单体;药理;心血管 经验分享：天塌了呀，BP也被on hold了(;´༎ຶД༎ຶ`), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Mon Oct 21 15:42:56 CST 2024, time=2024-10-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216713, encodeId=8b5d2216e13d5, content=偏重的研究方向：医药科学;药物治疗 经验分享：7月11号投的，66xx号，今天还是submitted。今年很慢，当然稿件数也比去年多了很多。各位with editor的到多少号了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Wed Jul 24 22:21:10 CST 2024, time=2024-07-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2229825, encodeId=fa30222982568, content=11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12929487465, createdName=ms2000001614134640, createdTime=Tue Oct 08 15:41:50 CST 2024, time=2024-10-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232108, encodeId=247d223210874, content=On Hold了，我哭了！已经wos检索了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Mon Oct 21 13:14:19 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2232128, encodeId=164e22321282b, content=期刊o n h o l d了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsmALpODGnWib5UaDNI6ztgdmKt9ib3ibKROqTEpGzjvlLbbTLHod3OMBdlb0fCVKtGlvodJCkmsL7Q/132, createdBy=d0d95098090, createdName=ms1469747388241577, createdTime=Mon Oct 21 13:53:56 CST 2024, time=2024-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2232156, encodeId=7bac2232156c0, content=文章返修的时候，就必须要提交所有原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c508657481, createdName=ms3000000739577335, createdTime=Mon Oct 21 16:04:09 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2230336, encodeId=e1852230336d1, content=偏重的研究方向：综述 经验分享：New submission一个月现在with editor又快两周了啥时候能决定送审或者拒稿啊也太慢了🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36a6166479, createdName=ms5000001867703342, createdTime=Fri Oct 11 14:14:16 CST 2024, time=2024-10-11, status=1, ipAttribution=江苏省)]

2024-09-17 ms1000000538363514 来自广东省

审稿速度:2.0 | 投稿命中率:95.0
偏重的研究方向：药学
经验分享：投完之后就后悔了 2个月就中了博士第一篇SCI 感觉以后会是污点但是为了毕业也是无奈之举单纯要毕业可以投如果不担心毕业别投了以后真的是污点现在真的后悔因为 2个月之后中了 SCIENCE SIGNALING

63 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226246, encodeId=b83e222624679, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：药学 经验分享：投完之后就后悔了 2个月就中了博士第一篇SCI 感觉以后会是污点但是为了毕业也是无奈之举单纯要毕业可以投如果不担心毕业别投了以后真的是污点现在真的后悔因为 2个月之后中了 SCIENCE SIGNALING , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c8550067, createdName=ms1000000538363514, createdTime=Tue Sep 17 20:03:25 CST 2024, time=2024-09-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232434, encodeId=a6562232434b3, content=On hold了！快跑！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a35599610, createdName=ms3000000650032694, createdTime=Tue Oct 22 14:04:58 CST 2024, time=2024-10-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233015, encodeId=96d12233015e5, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理学;癌症;神经退行性疾病 经验分享：《BIOMEDICINE & PHARMACOTHERAPY》，中文名《生物医学与药物治疗》在10月21日被on hold。 《BIOMEDICINE & PHARMACOTHERAPY》是医学—药学类目SCI期刊，创刊于1982年，由Elsevier 出版，该期刊主要发表生物医学和药理学相关的研究，涉及癌症、营养学、神经退行性疾病、心脏病和传染病的分子机制，正常和病理细胞的基因调节以及对致癌物质的敏感性，药物对临床前和临床药理学的影响，细菌、病毒和寄生虫在动物和人类中的作用等。国人喜欢这本期刊是因为该期刊对中医药研究比较友好。 中科院预警情况：2020年预警等级：中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Fri Oct 25 05:38:32 CST 2024, time=2024-10-25, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2232150, encodeId=bd1d2232150e3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：中药单体;药理;心血管 经验分享：天塌了呀，BP也被on hold了(;´༎ຶД༎ຶ`), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Mon Oct 21 15:42:56 CST 2024, time=2024-10-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216713, encodeId=8b5d2216e13d5, content=偏重的研究方向：医药科学;药物治疗 经验分享：7月11号投的，66xx号，今天还是submitted。今年很慢，当然稿件数也比去年多了很多。各位with editor的到多少号了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Wed Jul 24 22:21:10 CST 2024, time=2024-07-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2229825, encodeId=fa30222982568, content=11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12929487465, createdName=ms2000001614134640, createdTime=Tue Oct 08 15:41:50 CST 2024, time=2024-10-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232108, encodeId=247d223210874, content=On Hold了，我哭了！已经wos检索了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Mon Oct 21 13:14:19 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2232128, encodeId=164e22321282b, content=期刊o n h o l d了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsmALpODGnWib5UaDNI6ztgdmKt9ib3ibKROqTEpGzjvlLbbTLHod3OMBdlb0fCVKtGlvodJCkmsL7Q/132, createdBy=d0d95098090, createdName=ms1469747388241577, createdTime=Mon Oct 21 13:53:56 CST 2024, time=2024-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2232156, encodeId=7bac2232156c0, content=文章返修的时候，就必须要提交所有原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c508657481, createdName=ms3000000739577335, createdTime=Mon Oct 21 16:04:09 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2230336, encodeId=e1852230336d1, content=偏重的研究方向：综述 经验分享：New submission一个月现在with editor又快两周了啥时候能决定送审或者拒稿啊也太慢了🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36a6166479, createdName=ms5000001867703342, createdTime=Fri Oct 11 14:14:16 CST 2024, time=2024-10-11, status=1, ipAttribution=江苏省)]

2024-10-22 ms3000000650032694 来自广东省

On hold了！快跑！！

57 0

[GetPortalCommentsPageByObjectIdResponse(id=2226246, encodeId=b83e222624679, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：药学 经验分享：投完之后就后悔了 2个月就中了博士第一篇SCI 感觉以后会是污点但是为了毕业也是无奈之举单纯要毕业可以投如果不担心毕业别投了以后真的是污点现在真的后悔因为 2个月之后中了 SCIENCE SIGNALING , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c8550067, createdName=ms1000000538363514, createdTime=Tue Sep 17 20:03:25 CST 2024, time=2024-09-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232434, encodeId=a6562232434b3, content=On hold了！快跑！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a35599610, createdName=ms3000000650032694, createdTime=Tue Oct 22 14:04:58 CST 2024, time=2024-10-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233015, encodeId=96d12233015e5, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理学;癌症;神经退行性疾病 经验分享：《BIOMEDICINE & PHARMACOTHERAPY》，中文名《生物医学与药物治疗》在10月21日被on hold。 《BIOMEDICINE & PHARMACOTHERAPY》是医学—药学类目SCI期刊，创刊于1982年，由Elsevier 出版，该期刊主要发表生物医学和药理学相关的研究，涉及癌症、营养学、神经退行性疾病、心脏病和传染病的分子机制，正常和病理细胞的基因调节以及对致癌物质的敏感性，药物对临床前和临床药理学的影响，细菌、病毒和寄生虫在动物和人类中的作用等。国人喜欢这本期刊是因为该期刊对中医药研究比较友好。 中科院预警情况：2020年预警等级：中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Fri Oct 25 05:38:32 CST 2024, time=2024-10-25, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2232150, encodeId=bd1d2232150e3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：中药单体;药理;心血管 经验分享：天塌了呀，BP也被on hold了(;´༎ຶД༎ຶ`), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Mon Oct 21 15:42:56 CST 2024, time=2024-10-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216713, encodeId=8b5d2216e13d5, content=偏重的研究方向：医药科学;药物治疗 经验分享：7月11号投的，66xx号，今天还是submitted。今年很慢，当然稿件数也比去年多了很多。各位with editor的到多少号了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Wed Jul 24 22:21:10 CST 2024, time=2024-07-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2229825, encodeId=fa30222982568, content=11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12929487465, createdName=ms2000001614134640, createdTime=Tue Oct 08 15:41:50 CST 2024, time=2024-10-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232108, encodeId=247d223210874, content=On Hold了，我哭了！已经wos检索了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Mon Oct 21 13:14:19 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2232128, encodeId=164e22321282b, content=期刊o n h o l d了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsmALpODGnWib5UaDNI6ztgdmKt9ib3ibKROqTEpGzjvlLbbTLHod3OMBdlb0fCVKtGlvodJCkmsL7Q/132, createdBy=d0d95098090, createdName=ms1469747388241577, createdTime=Mon Oct 21 13:53:56 CST 2024, time=2024-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2232156, encodeId=7bac2232156c0, content=文章返修的时候，就必须要提交所有原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c508657481, createdName=ms3000000739577335, createdTime=Mon Oct 21 16:04:09 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2230336, encodeId=e1852230336d1, content=偏重的研究方向：综述 经验分享：New submission一个月现在with editor又快两周了啥时候能决定送审或者拒稿啊也太慢了🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36a6166479, createdName=ms5000001867703342, createdTime=Fri Oct 11 14:14:16 CST 2024, time=2024-10-11, status=1, ipAttribution=江苏省)]

2024-10-25 侠胆医心来自威斯康星

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：药理学;癌症;神经退行性疾病
经验分享：《BIOMEDICINE & PHARMACOTHERAPY》，中文名《生物医学与药物治疗》在10月21日被on hold。
《BIOMEDICINE & PHARMACOTHERAPY》是医学—药学类目SCI期刊，创刊于1982年，由Elsevier 出版，该期刊主要发表生物医学和药理学相关的研究，涉及癌症、营养学、神经退行性疾病、心脏病和传染病的分子机制，正常和病理细胞的基因调节以及对致癌物质的敏感性，药物对临床前和临床药理学的影响，细菌、病毒和寄生虫在动物和人类中的作用等。国人喜欢这本期刊是因为该期刊对中医药研究比较友好。
中科院预警情况：2020年预警等级：中

66 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226246, encodeId=b83e222624679, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：药学 经验分享：投完之后就后悔了 2个月就中了博士第一篇SCI 感觉以后会是污点但是为了毕业也是无奈之举单纯要毕业可以投如果不担心毕业别投了以后真的是污点现在真的后悔因为 2个月之后中了 SCIENCE SIGNALING , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c8550067, createdName=ms1000000538363514, createdTime=Tue Sep 17 20:03:25 CST 2024, time=2024-09-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232434, encodeId=a6562232434b3, content=On hold了！快跑！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a35599610, createdName=ms3000000650032694, createdTime=Tue Oct 22 14:04:58 CST 2024, time=2024-10-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233015, encodeId=96d12233015e5, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理学;癌症;神经退行性疾病 经验分享：《BIOMEDICINE & PHARMACOTHERAPY》，中文名《生物医学与药物治疗》在10月21日被on hold。 《BIOMEDICINE & PHARMACOTHERAPY》是医学—药学类目SCI期刊，创刊于1982年，由Elsevier 出版，该期刊主要发表生物医学和药理学相关的研究，涉及癌症、营养学、神经退行性疾病、心脏病和传染病的分子机制，正常和病理细胞的基因调节以及对致癌物质的敏感性，药物对临床前和临床药理学的影响，细菌、病毒和寄生虫在动物和人类中的作用等。国人喜欢这本期刊是因为该期刊对中医药研究比较友好。 中科院预警情况：2020年预警等级：中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Fri Oct 25 05:38:32 CST 2024, time=2024-10-25, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2232150, encodeId=bd1d2232150e3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：中药单体;药理;心血管 经验分享：天塌了呀，BP也被on hold了(;´༎ຶД༎ຶ`), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Mon Oct 21 15:42:56 CST 2024, time=2024-10-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216713, encodeId=8b5d2216e13d5, content=偏重的研究方向：医药科学;药物治疗 经验分享：7月11号投的，66xx号，今天还是submitted。今年很慢，当然稿件数也比去年多了很多。各位with editor的到多少号了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Wed Jul 24 22:21:10 CST 2024, time=2024-07-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2229825, encodeId=fa30222982568, content=11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12929487465, createdName=ms2000001614134640, createdTime=Tue Oct 08 15:41:50 CST 2024, time=2024-10-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232108, encodeId=247d223210874, content=On Hold了，我哭了！已经wos检索了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Mon Oct 21 13:14:19 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2232128, encodeId=164e22321282b, content=期刊o n h o l d了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsmALpODGnWib5UaDNI6ztgdmKt9ib3ibKROqTEpGzjvlLbbTLHod3OMBdlb0fCVKtGlvodJCkmsL7Q/132, createdBy=d0d95098090, createdName=ms1469747388241577, createdTime=Mon Oct 21 13:53:56 CST 2024, time=2024-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2232156, encodeId=7bac2232156c0, content=文章返修的时候，就必须要提交所有原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c508657481, createdName=ms3000000739577335, createdTime=Mon Oct 21 16:04:09 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2230336, encodeId=e1852230336d1, content=偏重的研究方向：综述 经验分享：New submission一个月现在with editor又快两周了啥时候能决定送审或者拒稿啊也太慢了🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36a6166479, createdName=ms5000001867703342, createdTime=Fri Oct 11 14:14:16 CST 2024, time=2024-10-11, status=1, ipAttribution=江苏省)]

2024-10-21 ms8000000847274971 来自广东省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：中药单体;药理;心血管
经验分享：天塌了呀，BP也被on hold了(;´༎ຶД༎ຶ`)

51 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226246, encodeId=b83e222624679, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：药学 经验分享：投完之后就后悔了 2个月就中了博士第一篇SCI 感觉以后会是污点但是为了毕业也是无奈之举单纯要毕业可以投如果不担心毕业别投了以后真的是污点现在真的后悔因为 2个月之后中了 SCIENCE SIGNALING , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c8550067, createdName=ms1000000538363514, createdTime=Tue Sep 17 20:03:25 CST 2024, time=2024-09-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232434, encodeId=a6562232434b3, content=On hold了！快跑！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a35599610, createdName=ms3000000650032694, createdTime=Tue Oct 22 14:04:58 CST 2024, time=2024-10-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233015, encodeId=96d12233015e5, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理学;癌症;神经退行性疾病 经验分享：《BIOMEDICINE & PHARMACOTHERAPY》，中文名《生物医学与药物治疗》在10月21日被on hold。 《BIOMEDICINE & PHARMACOTHERAPY》是医学—药学类目SCI期刊，创刊于1982年，由Elsevier 出版，该期刊主要发表生物医学和药理学相关的研究，涉及癌症、营养学、神经退行性疾病、心脏病和传染病的分子机制，正常和病理细胞的基因调节以及对致癌物质的敏感性，药物对临床前和临床药理学的影响，细菌、病毒和寄生虫在动物和人类中的作用等。国人喜欢这本期刊是因为该期刊对中医药研究比较友好。 中科院预警情况：2020年预警等级：中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Fri Oct 25 05:38:32 CST 2024, time=2024-10-25, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2232150, encodeId=bd1d2232150e3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：中药单体;药理;心血管 经验分享：天塌了呀，BP也被on hold了(;´༎ຶД༎ຶ`), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Mon Oct 21 15:42:56 CST 2024, time=2024-10-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216713, encodeId=8b5d2216e13d5, content=偏重的研究方向：医药科学;药物治疗 经验分享：7月11号投的，66xx号，今天还是submitted。今年很慢，当然稿件数也比去年多了很多。各位with editor的到多少号了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Wed Jul 24 22:21:10 CST 2024, time=2024-07-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2229825, encodeId=fa30222982568, content=11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12929487465, createdName=ms2000001614134640, createdTime=Tue Oct 08 15:41:50 CST 2024, time=2024-10-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232108, encodeId=247d223210874, content=On Hold了，我哭了！已经wos检索了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Mon Oct 21 13:14:19 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2232128, encodeId=164e22321282b, content=期刊o n h o l d了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsmALpODGnWib5UaDNI6ztgdmKt9ib3ibKROqTEpGzjvlLbbTLHod3OMBdlb0fCVKtGlvodJCkmsL7Q/132, createdBy=d0d95098090, createdName=ms1469747388241577, createdTime=Mon Oct 21 13:53:56 CST 2024, time=2024-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2232156, encodeId=7bac2232156c0, content=文章返修的时候，就必须要提交所有原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c508657481, createdName=ms3000000739577335, createdTime=Mon Oct 21 16:04:09 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2230336, encodeId=e1852230336d1, content=偏重的研究方向：综述 经验分享：New submission一个月现在with editor又快两周了啥时候能决定送审或者拒稿啊也太慢了🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36a6166479, createdName=ms5000001867703342, createdTime=Fri Oct 11 14:14:16 CST 2024, time=2024-10-11, status=1, ipAttribution=江苏省)]

2024-07-24 少吃一口来自四川省

偏重的研究方向：医药科学;药物治疗
经验分享：7月11号投的，66xx号，今天还是submitted。今年很慢，当然稿件数也比去年多了很多。各位with editor的到多少号了？

114 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226246, encodeId=b83e222624679, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：药学 经验分享：投完之后就后悔了 2个月就中了博士第一篇SCI 感觉以后会是污点但是为了毕业也是无奈之举单纯要毕业可以投如果不担心毕业别投了以后真的是污点现在真的后悔因为 2个月之后中了 SCIENCE SIGNALING , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c8550067, createdName=ms1000000538363514, createdTime=Tue Sep 17 20:03:25 CST 2024, time=2024-09-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232434, encodeId=a6562232434b3, content=On hold了！快跑！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a35599610, createdName=ms3000000650032694, createdTime=Tue Oct 22 14:04:58 CST 2024, time=2024-10-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233015, encodeId=96d12233015e5, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理学;癌症;神经退行性疾病 经验分享：《BIOMEDICINE & PHARMACOTHERAPY》，中文名《生物医学与药物治疗》在10月21日被on hold。 《BIOMEDICINE & PHARMACOTHERAPY》是医学—药学类目SCI期刊，创刊于1982年，由Elsevier 出版，该期刊主要发表生物医学和药理学相关的研究，涉及癌症、营养学、神经退行性疾病、心脏病和传染病的分子机制，正常和病理细胞的基因调节以及对致癌物质的敏感性，药物对临床前和临床药理学的影响，细菌、病毒和寄生虫在动物和人类中的作用等。国人喜欢这本期刊是因为该期刊对中医药研究比较友好。 中科院预警情况：2020年预警等级：中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Fri Oct 25 05:38:32 CST 2024, time=2024-10-25, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2232150, encodeId=bd1d2232150e3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：中药单体;药理;心血管 经验分享：天塌了呀，BP也被on hold了(;´༎ຶД༎ຶ`), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Mon Oct 21 15:42:56 CST 2024, time=2024-10-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216713, encodeId=8b5d2216e13d5, content=偏重的研究方向：医药科学;药物治疗 经验分享：7月11号投的，66xx号，今天还是submitted。今年很慢，当然稿件数也比去年多了很多。各位with editor的到多少号了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Wed Jul 24 22:21:10 CST 2024, time=2024-07-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2229825, encodeId=fa30222982568, content=11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12929487465, createdName=ms2000001614134640, createdTime=Tue Oct 08 15:41:50 CST 2024, time=2024-10-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232108, encodeId=247d223210874, content=On Hold了，我哭了！已经wos检索了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Mon Oct 21 13:14:19 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2232128, encodeId=164e22321282b, content=期刊o n h o l d了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsmALpODGnWib5UaDNI6ztgdmKt9ib3ibKROqTEpGzjvlLbbTLHod3OMBdlb0fCVKtGlvodJCkmsL7Q/132, createdBy=d0d95098090, createdName=ms1469747388241577, createdTime=Mon Oct 21 13:53:56 CST 2024, time=2024-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2232156, encodeId=7bac2232156c0, content=文章返修的时候，就必须要提交所有原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c508657481, createdName=ms3000000739577335, createdTime=Mon Oct 21 16:04:09 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2230336, encodeId=e1852230336d1, content=偏重的研究方向：综述 经验分享：New submission一个月现在with editor又快两周了啥时候能决定送审或者拒稿啊也太慢了🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36a6166479, createdName=ms5000001867703342, createdTime=Fri Oct 11 14:14:16 CST 2024, time=2024-10-11, status=1, ipAttribution=江苏省)]

2024-10-08 ms2000001614134640 来自湖南省

11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted

63 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226246, encodeId=b83e222624679, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：药学 经验分享：投完之后就后悔了 2个月就中了博士第一篇SCI 感觉以后会是污点但是为了毕业也是无奈之举单纯要毕业可以投如果不担心毕业别投了以后真的是污点现在真的后悔因为 2个月之后中了 SCIENCE SIGNALING , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c8550067, createdName=ms1000000538363514, createdTime=Tue Sep 17 20:03:25 CST 2024, time=2024-09-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232434, encodeId=a6562232434b3, content=On hold了！快跑！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a35599610, createdName=ms3000000650032694, createdTime=Tue Oct 22 14:04:58 CST 2024, time=2024-10-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233015, encodeId=96d12233015e5, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理学;癌症;神经退行性疾病 经验分享：《BIOMEDICINE & PHARMACOTHERAPY》，中文名《生物医学与药物治疗》在10月21日被on hold。 《BIOMEDICINE & PHARMACOTHERAPY》是医学—药学类目SCI期刊，创刊于1982年，由Elsevier 出版，该期刊主要发表生物医学和药理学相关的研究，涉及癌症、营养学、神经退行性疾病、心脏病和传染病的分子机制，正常和病理细胞的基因调节以及对致癌物质的敏感性，药物对临床前和临床药理学的影响，细菌、病毒和寄生虫在动物和人类中的作用等。国人喜欢这本期刊是因为该期刊对中医药研究比较友好。 中科院预警情况：2020年预警等级：中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Fri Oct 25 05:38:32 CST 2024, time=2024-10-25, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2232150, encodeId=bd1d2232150e3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：中药单体;药理;心血管 经验分享：天塌了呀，BP也被on hold了(;´༎ຶД༎ຶ`), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Mon Oct 21 15:42:56 CST 2024, time=2024-10-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216713, encodeId=8b5d2216e13d5, content=偏重的研究方向：医药科学;药物治疗 经验分享：7月11号投的，66xx号，今天还是submitted。今年很慢，当然稿件数也比去年多了很多。各位with editor的到多少号了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Wed Jul 24 22:21:10 CST 2024, time=2024-07-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2229825, encodeId=fa30222982568, content=11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12929487465, createdName=ms2000001614134640, createdTime=Tue Oct 08 15:41:50 CST 2024, time=2024-10-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232108, encodeId=247d223210874, content=On Hold了，我哭了！已经wos检索了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Mon Oct 21 13:14:19 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2232128, encodeId=164e22321282b, content=期刊o n h o l d了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsmALpODGnWib5UaDNI6ztgdmKt9ib3ibKROqTEpGzjvlLbbTLHod3OMBdlb0fCVKtGlvodJCkmsL7Q/132, createdBy=d0d95098090, createdName=ms1469747388241577, createdTime=Mon Oct 21 13:53:56 CST 2024, time=2024-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2232156, encodeId=7bac2232156c0, content=文章返修的时候，就必须要提交所有原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c508657481, createdName=ms3000000739577335, createdTime=Mon Oct 21 16:04:09 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2230336, encodeId=e1852230336d1, content=偏重的研究方向：综述 经验分享：New submission一个月现在with editor又快两周了啥时候能决定送审或者拒稿啊也太慢了🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36a6166479, createdName=ms5000001867703342, createdTime=Fri Oct 11 14:14:16 CST 2024, time=2024-10-11, status=1, ipAttribution=江苏省)]

2024-10-21 chy 来自辽宁省

On Hold了，我哭了！已经wos检索了

54 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226246, encodeId=b83e222624679, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：药学 经验分享：投完之后就后悔了 2个月就中了博士第一篇SCI 感觉以后会是污点但是为了毕业也是无奈之举单纯要毕业可以投如果不担心毕业别投了以后真的是污点现在真的后悔因为 2个月之后中了 SCIENCE SIGNALING , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c8550067, createdName=ms1000000538363514, createdTime=Tue Sep 17 20:03:25 CST 2024, time=2024-09-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232434, encodeId=a6562232434b3, content=On hold了！快跑！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a35599610, createdName=ms3000000650032694, createdTime=Tue Oct 22 14:04:58 CST 2024, time=2024-10-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233015, encodeId=96d12233015e5, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理学;癌症;神经退行性疾病 经验分享：《BIOMEDICINE & PHARMACOTHERAPY》，中文名《生物医学与药物治疗》在10月21日被on hold。 《BIOMEDICINE & PHARMACOTHERAPY》是医学—药学类目SCI期刊，创刊于1982年，由Elsevier 出版，该期刊主要发表生物医学和药理学相关的研究，涉及癌症、营养学、神经退行性疾病、心脏病和传染病的分子机制，正常和病理细胞的基因调节以及对致癌物质的敏感性，药物对临床前和临床药理学的影响，细菌、病毒和寄生虫在动物和人类中的作用等。国人喜欢这本期刊是因为该期刊对中医药研究比较友好。 中科院预警情况：2020年预警等级：中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Fri Oct 25 05:38:32 CST 2024, time=2024-10-25, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2232150, encodeId=bd1d2232150e3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：中药单体;药理;心血管 经验分享：天塌了呀，BP也被on hold了(;´༎ຶД༎ຶ`), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Mon Oct 21 15:42:56 CST 2024, time=2024-10-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216713, encodeId=8b5d2216e13d5, content=偏重的研究方向：医药科学;药物治疗 经验分享：7月11号投的，66xx号，今天还是submitted。今年很慢，当然稿件数也比去年多了很多。各位with editor的到多少号了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Wed Jul 24 22:21:10 CST 2024, time=2024-07-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2229825, encodeId=fa30222982568, content=11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12929487465, createdName=ms2000001614134640, createdTime=Tue Oct 08 15:41:50 CST 2024, time=2024-10-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232108, encodeId=247d223210874, content=On Hold了，我哭了！已经wos检索了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Mon Oct 21 13:14:19 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2232128, encodeId=164e22321282b, content=期刊o n h o l d了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsmALpODGnWib5UaDNI6ztgdmKt9ib3ibKROqTEpGzjvlLbbTLHod3OMBdlb0fCVKtGlvodJCkmsL7Q/132, createdBy=d0d95098090, createdName=ms1469747388241577, createdTime=Mon Oct 21 13:53:56 CST 2024, time=2024-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2232156, encodeId=7bac2232156c0, content=文章返修的时候，就必须要提交所有原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c508657481, createdName=ms3000000739577335, createdTime=Mon Oct 21 16:04:09 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2230336, encodeId=e1852230336d1, content=偏重的研究方向：综述 经验分享：New submission一个月现在with editor又快两周了啥时候能决定送审或者拒稿啊也太慢了🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36a6166479, createdName=ms5000001867703342, createdTime=Fri Oct 11 14:14:16 CST 2024, time=2024-10-11, status=1, ipAttribution=江苏省)]

2024-10-21 ms1469747388241577

期刊o n h o l d了

61 0

[GetPortalCommentsPageByObjectIdResponse(id=2226246, encodeId=b83e222624679, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：药学 经验分享：投完之后就后悔了 2个月就中了博士第一篇SCI 感觉以后会是污点但是为了毕业也是无奈之举单纯要毕业可以投如果不担心毕业别投了以后真的是污点现在真的后悔因为 2个月之后中了 SCIENCE SIGNALING , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c8550067, createdName=ms1000000538363514, createdTime=Tue Sep 17 20:03:25 CST 2024, time=2024-09-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232434, encodeId=a6562232434b3, content=On hold了！快跑！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a35599610, createdName=ms3000000650032694, createdTime=Tue Oct 22 14:04:58 CST 2024, time=2024-10-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233015, encodeId=96d12233015e5, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理学;癌症;神经退行性疾病 经验分享：《BIOMEDICINE & PHARMACOTHERAPY》，中文名《生物医学与药物治疗》在10月21日被on hold。 《BIOMEDICINE & PHARMACOTHERAPY》是医学—药学类目SCI期刊，创刊于1982年，由Elsevier 出版，该期刊主要发表生物医学和药理学相关的研究，涉及癌症、营养学、神经退行性疾病、心脏病和传染病的分子机制，正常和病理细胞的基因调节以及对致癌物质的敏感性，药物对临床前和临床药理学的影响，细菌、病毒和寄生虫在动物和人类中的作用等。国人喜欢这本期刊是因为该期刊对中医药研究比较友好。 中科院预警情况：2020年预警等级：中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Fri Oct 25 05:38:32 CST 2024, time=2024-10-25, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2232150, encodeId=bd1d2232150e3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：中药单体;药理;心血管 经验分享：天塌了呀，BP也被on hold了(;´༎ຶД༎ຶ`), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Mon Oct 21 15:42:56 CST 2024, time=2024-10-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216713, encodeId=8b5d2216e13d5, content=偏重的研究方向：医药科学;药物治疗 经验分享：7月11号投的，66xx号，今天还是submitted。今年很慢，当然稿件数也比去年多了很多。各位with editor的到多少号了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Wed Jul 24 22:21:10 CST 2024, time=2024-07-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2229825, encodeId=fa30222982568, content=11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12929487465, createdName=ms2000001614134640, createdTime=Tue Oct 08 15:41:50 CST 2024, time=2024-10-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232108, encodeId=247d223210874, content=On Hold了，我哭了！已经wos检索了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Mon Oct 21 13:14:19 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2232128, encodeId=164e22321282b, content=期刊o n h o l d了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsmALpODGnWib5UaDNI6ztgdmKt9ib3ibKROqTEpGzjvlLbbTLHod3OMBdlb0fCVKtGlvodJCkmsL7Q/132, createdBy=d0d95098090, createdName=ms1469747388241577, createdTime=Mon Oct 21 13:53:56 CST 2024, time=2024-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2232156, encodeId=7bac2232156c0, content=文章返修的时候，就必须要提交所有原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c508657481, createdName=ms3000000739577335, createdTime=Mon Oct 21 16:04:09 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2230336, encodeId=e1852230336d1, content=偏重的研究方向：综述 经验分享：New submission一个月现在with editor又快两周了啥时候能决定送审或者拒稿啊也太慢了🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36a6166479, createdName=ms5000001867703342, createdTime=Fri Oct 11 14:14:16 CST 2024, time=2024-10-11, status=1, ipAttribution=江苏省)]

2024-10-21 ms3000000739577335 来自辽宁省

文章返修的时候，就必须要提交所有原始数据吗？

50 0

[GetPortalCommentsPageByObjectIdResponse(id=2226246, encodeId=b83e222624679, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：药学 经验分享：投完之后就后悔了 2个月就中了博士第一篇SCI 感觉以后会是污点但是为了毕业也是无奈之举单纯要毕业可以投如果不担心毕业别投了以后真的是污点现在真的后悔因为 2个月之后中了 SCIENCE SIGNALING , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c8550067, createdName=ms1000000538363514, createdTime=Tue Sep 17 20:03:25 CST 2024, time=2024-09-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232434, encodeId=a6562232434b3, content=On hold了！快跑！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a35599610, createdName=ms3000000650032694, createdTime=Tue Oct 22 14:04:58 CST 2024, time=2024-10-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233015, encodeId=96d12233015e5, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理学;癌症;神经退行性疾病 经验分享：《BIOMEDICINE & PHARMACOTHERAPY》，中文名《生物医学与药物治疗》在10月21日被on hold。 《BIOMEDICINE & PHARMACOTHERAPY》是医学—药学类目SCI期刊，创刊于1982年，由Elsevier 出版，该期刊主要发表生物医学和药理学相关的研究，涉及癌症、营养学、神经退行性疾病、心脏病和传染病的分子机制，正常和病理细胞的基因调节以及对致癌物质的敏感性，药物对临床前和临床药理学的影响，细菌、病毒和寄生虫在动物和人类中的作用等。国人喜欢这本期刊是因为该期刊对中医药研究比较友好。 中科院预警情况：2020年预警等级：中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Fri Oct 25 05:38:32 CST 2024, time=2024-10-25, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2232150, encodeId=bd1d2232150e3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：中药单体;药理;心血管 经验分享：天塌了呀，BP也被on hold了(;´༎ຶД༎ຶ`), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Mon Oct 21 15:42:56 CST 2024, time=2024-10-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216713, encodeId=8b5d2216e13d5, content=偏重的研究方向：医药科学;药物治疗 经验分享：7月11号投的，66xx号，今天还是submitted。今年很慢，当然稿件数也比去年多了很多。各位with editor的到多少号了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Wed Jul 24 22:21:10 CST 2024, time=2024-07-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2229825, encodeId=fa30222982568, content=11-17Submit New Manuscript 12-7Submissions Sent Back to Author 要求更改WB原始数据格式 12-13Submit New Manuscript 1-11With editor 1-14、1-16 1-17 1-29 Under review 2-13 Required Reviews completed 2-14Decision in progress 2-17Revise 3-7Revised Manuscript Submitted 3-7Under Review 3-15Revise 3-28 Revision submitted to journal 3-28Under Review 4-1Required Reviews Completed 4-4 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12929487465, createdName=ms2000001614134640, createdTime=Tue Oct 08 15:41:50 CST 2024, time=2024-10-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232108, encodeId=247d223210874, content=On Hold了，我哭了！已经wos检索了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Mon Oct 21 13:14:19 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2232128, encodeId=164e22321282b, content=期刊o n h o l d了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsmALpODGnWib5UaDNI6ztgdmKt9ib3ibKROqTEpGzjvlLbbTLHod3OMBdlb0fCVKtGlvodJCkmsL7Q/132, createdBy=d0d95098090, createdName=ms1469747388241577, createdTime=Mon Oct 21 13:53:56 CST 2024, time=2024-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2232156, encodeId=7bac2232156c0, content=文章返修的时候，就必须要提交所有原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c508657481, createdName=ms3000000739577335, createdTime=Mon Oct 21 16:04:09 CST 2024, time=2024-10-21, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2230336, encodeId=e1852230336d1, content=偏重的研究方向：综述 经验分享：New submission一个月现在with editor又快两周了啥时候能决定送审或者拒稿啊也太慢了🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36a6166479, createdName=ms5000001867703342, createdTime=Fri Oct 11 14:14:16 CST 2024, time=2024-10-11, status=1, ipAttribution=江苏省)]

2024-10-11 ms5000001867703342 来自江苏省

偏重的研究方向：综述
经验分享：New submission一个月现在with editor又快两周了啥时候能决定送审或者拒稿啊也太慢了🥲

64 4

展开4条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务